Allos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule therapeutics for the treatment of cancer. Its lead product candidate, PDX (pralatrexate), is a novel antifolate under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. Its other product candidate is RH1, a targeted chemotherapeutic agent, under evaluation in Phase 1 in patients with advanced solid tumors or non-Hodgkin's Lymphoma. Allos Therapeutics was founded in 1992. It was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in 1994. The company is headquartered in Westminster, Colorado.
Analysts'
Recommendation: | Buy |
| 30 Days Ago: | Buy |
|
| Analysts' Target: | $10 |
| Analysts' Targets |
| Citigroup | $11 |
| Buy |
Thursday, June 26, 2008
|
| Needham & Co. | $10 |
| Buy |
Thursday, February 28, 2008
|
| Collins Stewart LLC | $9 |
| Buy |
Thursday, February 28, 2008
|
$8.0 (07/15/08)
